Investment Thesis
Revelation Biosciences is a pre-revenue biotech company with severe operational challenges despite a strong cash position. With negative operating cash flow of -$8.3M annually and only ~$10.7M in cash, the company faces approximately 1.3 years of runway at current burn rates, creating an urgent need for clinical milestone achievement, revenue generation, or capital raise to avoid financial distress.
Strengths
- Strong liquidity position with 5.41x current ratio and $10.7M cash reserves
- Zero debt burden with clean balance sheet (0.0x debt/equity ratio)
- Improving loss trajectory with 40% YoY improvement in net income
Risks
- Completely pre-revenue with no commercial sales generating cash
- Negative operating cash flow of -$8.3M annually creates only 1.3 years of cash runway at current burn rate
- Persistent unprofitability with -100.6% ROE and -77.0% ROA indicating destruction of shareholder value
Key Metrics to Watch
- Cash burn rate trend and total runway months remaining
- Clinical trial progress and regulatory milestone announcements
- Capital raise activities and equity dilution impacts
Financial Metrics
Revenue
N/A
Net Income
-8.9M
EPS (Diluted)
$-23.95
Free Cash Flow
-8.3M
Total Assets
11.6M
Cash
10.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-100.6%
ROA
-77.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
5.41x
Quick Ratio
5.41x
Debt/Equity
0.00x
Debt/Assets
23.5%
Interest Coverage
-217.22x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-08T22:30:20.632150 |
Data as of: 2025-12-31 |
Powered by Claude AI